Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Olcegepant – Novel Therapy for Acute Migraine

Drug (brand/generic)

Olcegepant (BIBN 4096)

Company/licensee

Boehringer Ingelheim Pharmaceuticals

Therapy class

Selective Calcitonin Gene-Related Peptide (CGRP) antagonist

Product description

Inhibits the release and action of Calcitonin Gene-Related Peptide (CGRP)

Current indication

Acute migraine

Market sector

CNS, analgesics

Development status

Phase II
Expand
Close
Close
Close

Go Top